Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-based therapies for patients with AML, a pertinent...

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Chong Chyn, Hammond, Danielle, Kent, Andrew, Tiong, Ing Soo, Konopleva, Marina Y., Pollyea, Daniel A., DiNardo, Courtney D., Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278306/
https://www.ncbi.nlm.nih.gov/pubmed/35511730
http://dx.doi.org/10.1182/bloodadvances.2022007083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278306/
https://www.ncbi.nlm.nih.gov/pubmed/35511730
http://dx.doi.org/10.1182/bloodadvances.2022007083

Ejemplares similares